LAVA Therapeutics N.V. Ordinary Shares - LVTX STOCK NEWS

LAVA Therapeutics presented initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 at the 2022 ASCO Annual Meeting. The trial targets patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) and observed a favorable safety profile with no dose-limiting toxicity observed. Potential early signs of anti-tumor activity were reported, with a CLL patient showing stable disease after 12 weeks and a MM patient experiencing a 23% reduction in M-protein levels. LAVA-051 is designed to engage Vγ9Vδ2 T cells and is on track for further data release.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that its Annual General Meeting of Shareholders is set for June 15, 2022, at 7:30 a.m. CEST in Amsterdam, Netherlands. Important documents regarding the meeting, including the notice and agenda, are accessible through LAVA’s investor website and the SEC. LAVA Therapeutics is focused on immuno-oncology, utilizing its Gammabody™ technology to develop bispecific gamma delta T cell engagers targeting solid and hematologic cancers. The lead candidate, LAVA-051, is in a Phase 1/2a clinical study for multiple myeloma and other malignancies.

LAVA Therapeutics N.V. (Nasdaq: LVTX) reported recent advancements in its immuno-oncology pipeline and financial results for Q1 2022. The company is in Phase 1/2a trials for LAVA-051 and LAVA-1207 targeting hematological malignancies and prostate cancer, respectively. Cash and investments totaled $124.2 million as of March 31, 2022. R&D expenses decreased to $7.6 million, while G&A expenses rose to $4.3 million, leading to a net loss of $10.6 million, or $0.41 per share. Initial data presentations at the ASCO Annual Meeting are anticipated in June 2022.

LAVA Therapeutics (Nasdaq: LVTX) announced FDA clearance of its IND application for LAVA-051, its leading candidate aimed at treating relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and acute myeloid leukemia (AML). This marks LAVA's second IND approval, allowing expanded patient enrollment in its Phase 1/2a trial. LAVA-051 is designed to activate immune T cells to combat CD1d-expressing tumors. The company will present interim trial data at the 2022 ASCO Annual Meeting, with previous Orphan Drug Designation granted for LAVA-051 to treat CLL.

LAVA Therapeutics (Nasdaq: LVTX) announced that Stephen Hurly, CEO, will participate in a fireside chat at the UBS Global Healthcare Conference 2022.

Event Details:

• Date: May 23, 2022
• Time: 4:15-4:45 PM ET

A live webcast and replay will be available on the company's investor relations website. LAVA Therapeutics focuses on developing its proprietary Gammabody™ platform targeting cancer treatment.

LAVA Therapeutics (Nasdaq: LVTX) announced it will present updated interim data from the dose escalation phase of its Phase 1/2a clinical trial for LAVA-051, targeted at relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). This presentation will take place at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The session is scheduled for June 5, and will be led by Dr. Benjamin Winograd, LAVA's Chief Medical Officer. The trial seeks to evaluate the effectiveness of LAVA-051 as a bispecific gamma delta T-cell engager.

LAVA Therapeutics N.V. (Nasdaq: LVTX) reported promising developments in its clinical trials for LAVA-051 and LAVA-1207, with initial safety data showing no dose-limiting toxicities. The company also introduced a new pipeline candidate, LAVA-1266, targeting hematological malignancies. As of December 31, 2021, LAVA's financial position strengthened with cash and investments totaling $133.2 million, a significant increase from $15.8 million in 2020. However, the company reported a net loss of $45.3 million for 2021, reflecting rising operational expenses.

LAVA Therapeutics N.V. (Nasdaq: LVTX) announced that CEO Stephen Hurly will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, from 8:40 – 9:10 a.m. ET. The presentation will provide an overview of the company, which develops bispecific gamma delta T cell engagers (bsTCEs) for cancer treatment. The conference will be virtual, and a recording will be available post-event on their website. LAVA is currently enrolling patients in a Phase 1/2a study for LAVA-051 and LAVA-1207 to treat hematological malignancies and mCRPC, respectively.

LAVA Therapeutics (Nasdaq: LVTX) recently shared promising preliminary data from its Phase 1/2a clinical trial of LAVA-051, an investigational Gammabody™ designed to engage Vγ9Vδ2 T cells for cancer treatment. The initial cohorts demonstrated no dose-limiting toxicities or cytokine release syndrome (CRS), indicating a favorable safety profile. Observations showed increased receptor occupancy and T cell activation with dose escalation. Future data is expected in Q2 2022, and LAVA plans to file an IND application with the FDA to include U.S. patients.